

EQA round: AIH1/23 - Autoimmune Liver Diseases

Deadline: 10.3.2023

Setup: groups - measurement principle

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessed

CVP = consensus of all participants

N_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
(451) AMA		53			53	52	98
Sample A		53			53	52	98
(1) Fluorescent methods		1	1,9	Negative			
	CVP >>>	52	98	Positive			
Sample B		53			53	53	100
(1) Fluorescent methods	CVP >>>	53	100	Negative			
(456) AMA-M2		63			63	62	98
Sample A		63			63	63	100
(1) Fluorescent methods	CVP >>>	1	1,6	Positive			
(2) EIA methods	CVP >>>	11	17	Positive			
(5) Immunoblotting	CVP >>>	51	81	Positive			
Sample B		63			63	62	98
(1) Fluorescent methods	CVP >>>	1	1,6	Negative			
(2) EIA methods	CVP >>>	11	17	Negative			
(5) Immunoblotting	CVP >>>	50	79	Negative			
		1	1,6	Positive			
(454) anti-gp210		49			49	49	100
Sample A		49			49	49	100
(2) EIA methods	CVP >>>	1	2	Positive			
(5) Immunoblotting	CVP >>>	48	98	Positive			
Sample B		49			49	49	100
(2) EIA methods	CVP >>>	1	2	Negative			
(5) Immunoblotting	CVP >>>	48	98	Negative			
(457) anti-LC-1		58			58	58	100
Sample A		58			58	58	100
(2) EIA methods	CVP >>>	4	6,9	Negative			
(5) Immunoblotting	CVP >>>	54	93	Negative			
Sample B		58			58	58	100
(2) EIA methods	CVP >>>	4	6,9	Negative			
(5) Immunoblotting	CVP >>>	54	93	Negative			
(452) anti-LKM		46			46	45	98
Sample A		46			46	46	100
(1) Fluorescent methods	CVP >>>	46	100	Negative			
Sample B		46			46	45	98
(1) Fluorescent methods	CVP >>>	45	98	Negative			
		1	2,2	Positive			
(455) anti-LKM1		62			62	62	100
Sample A		62			62	62	100
(1) Fluorescent methods	CVP >>>	1	1,6	Negative			
(2) EIA methods	CVP >>>	12	19	Negative			
(5) Immunoblotting	CVP >>>	49	79	Negative			
Sample B		62			62	62	100
(1) Fluorescent methods	CVP >>>	1	1,6	Negative			
(2) EIA methods	CVP >>>	12	19	Negative			
(5) Immunoblotting	CVP >>>	49	79	Negative			
(458) anti-SLA		60			60	60	100
Sample A		60			60	60	100
(2) EIA methods	CVP >>>	8	13	Negative			
(5) Immunoblotting	CVP >>>	52	87	Negative			
Sample B		60			60	60	100
(2) EIA methods	CVP >>>	8	13	Negative			
(5) Immunoblotting	CVP >>>	52	87	Negative			
(459) anti-sp100		49			0		
Sample A		49			0		
(2) EIA methods	±	1	2	Positive			
(5) Immunoblotting	±	10	20	Negative			
	±	13	27	Inconclusive result (borderline)			
	±	25	51	Positive			
Sample B		49			0		
(2) EIA methods	±	1	2	Negative			
(5) Immunoblotting	±	37	76	Negative			
	±	7	14	Inconclusive result (borderline)			
	±	4	8,2	Positive			

EQA round: AIH1/23 - Autoimmune Liver Diseases

Deadline: 10.3.2023

Setup: groups - measurement principle

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
(453) SMA		54			54	54	100
Sample A		54			54	54	100
(1) Fluorescent methods	CVP >>>	53	98	Negative			
(5) Immunoblotting	CVP >>>	1	1,9	Negative			
Sample B		54			54	54	100
(1) Fluorescent methods	CVP >>>	53	98	Negative			
(5) Immunoblotting	CVP >>>	1	1,9	Negative			